1Duan Z, Brakora KA, Seiden MV. Inhibitian of ABOB1 (MDR1) and ABCD4 ( MDR3 ) expression by small interfering RNA and reversal of paclitexel resistance in human ovarian cancer cells [J]. Mol Cancer Ther, 2004, 3(7) :833 -838.
2Krasznai T, Friedlander E, Nagy A, et al. Quantitative and functional assay of patients MDR1/p170-mediated MDR in ascites cells of patients with ovarian cancer[J]. Anticancer Res, 2005,25 (2A) : 1187 - 1192.
6Kolfsehoten GM, Hulscher TM, Pinedo HM, et al. Druge resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts [ J ]. Br J Cancer,2000,83 (7) : 921 - 927,.
8Surowiak P, Matema V, Kaplenko I, et al. Augmented expression of metallothionein and Glutat-hione S- transferast pias unfavourable prognostic factors in cisplatin-treated ovarian cancer patients [ J ]. Virchous Arch, 2005,447 (3) 626 - 633.
9Beeghly A, Katsaros D, Chen H, et al. Glutathione S- transferase polymorphisms and ovarian cancer treatment and survival [ J ]. Gynecol Oncol, 2006,100 ( 2 ) : 330 - 337.
10Nakayama K, Kanzaki A, Ogowa K, et al. Copper- transporting P type adenosine triphosph-osphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma : comparative analysis with experssion of MDRI, MRPI, MRP2, LRP and BCRP [J]. Int J Cancer,2002,101 (5) :482 -495.
7Diatchenko L, Lau YF, Campbell AP, et al. Suppression subtractive hybridization:a method for generating differentially regulated or tissue-specific cDNA probes and libraries[J]. Proc Natl Acad Sci U S A,1996,93:6025-6030
8Hart SN, Wang S, Nakamoto K, et al. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism[ J]. Pharmacogenet Genomics, 2008,18 : 11-24
9Simsek T, Ozbilim G, Gulkesen H, et al. Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutation S- transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy [ J ]. Eur J Gynaecol 0ncol,2001,22 : 436-438
10Romani AA, Crafa P, Desenzani S, et al. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma [ J ]. BMC Cancer, 2007,7 : 232- 234
